Coherus BioSciences
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 3 | ×1.50 | 3 |
Strategy profile
Based on 6 disclosed transactions, Coherus BioSciences concentrates its licensing activity in Oncology. Coherus BioSciences pays a 1.50x premium over market median, with the strongest premiums in Oncology (1.50x). Their most common deal structure is Collaboration, with an average disclosed value of $634M. Most recent activity: 2023.
Premium by therapeutic area
How Coherus BioSciences pays relative to peer medians in each TA
Pipeline coverage & gaps
Coherus BioSciences has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 3 | $150M | $1.1B |
| Acquisition | 2 | $40M | $66M |
| Option | 1 | $35M | $290M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2023 | SRF388 (casdozokitug) and SRF114 (CHS-114) | Surface Oncology | oncology (immuno-oncology) | phase_1 | — | $65M |
| 2023 | Surface Oncology (company acquisition) | Surface Oncology | oncology (not HCC-specific) | unknown | $40M | $67M |
| 2022 | JS006 | Shanghai Junshi Biosciences Co., Ltd. | advanced solid tumors | phase_1 | $35M | $290M |
| 2021 | Toripalimab (JS-001) | Junshi Biosciences | nasopharyngeal carcinoma (among other indications) | phase_3 | $150M | $1.2B |
| 2021 | Toripalimab (JS001) | Shanghai Junshi Biosciences Co., Ltd. | nasopharyngeal carcinoma | phase_3 | $150M | $1.1B |
| 2021 | toripalimab | Shanghai Junshi Biosciences Co., Ltd | nasopharyngeal carcinoma, nsclc, melanoma, esophageal, gastric, bladder, breast, liver, kidney, soft tissue sarcoma | phase_3 | $150M | $1.1B |
How this is computed
For each Coherus BioSciences deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 2.688, clamped to [0.7, 1.5].